文献速递肝病消化道肿瘤与早癌

原发性低胆固醇血症与普通人群肝脏并发症风险增加相关

Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
PubMed 文献 · J Hepatol · 2024-02-06

基于法国CONSTANCES队列和英国UK Biobank队列,比较原发性低β脂蛋白血症(HBL,LDL-C低于年龄性别第5百分位)与正常LDL-C者的肝脏并发症风险。HBL组肝脏并发症发生率显著更高,CONSTANCES的IDR=4.50(95%CI 1.91-10.6),UKBB的IDR=3.27(95%CI 2.63-4.06),且独立于肥胖、饮酒、糖尿病、病毒性肝炎等经典危险因素。

要点

  • HBL与肝脏并发症风险显著增加相关,两个队列IDR分别为4.50和3.27。
  • 该风险独立于肥胖、饮酒、糖尿病和病毒性肝炎等经典肝病危险因素。
  • 基于载脂蛋白B或基因定义HBL的敏感性分析结果相似。

核心结论

  • 原发性低β脂蛋白血症(HBL)与肝脏并发症风险显著增加相关,应视为肝病的重要独立危险因素。

研究设计与样本

  • 在法国人群队列CONSTANCES中开展队列研究,HBL组为LDL-C低于年龄性别第5百分位者,对照组为LDL-C第40-60百分位者,并排除使用降脂治疗者。
  • 在UK Biobank(UKBB)队列中重复相同分析。
  • CONSTANCES纳入34,653人,中位年龄45岁,平均随访5.0年;UKBB纳入94,666人,中位年龄56岁,平均随访11.5年。

主要发现

  • CONSTANCES中HBL组与对照组肝脏并发症发生率分别为0.32/1000人年和0.07/1000人年,IDR=4.50(95%CI 1.91-10.6)。
  • UKBB中HBL组与对照组肝脏并发症发生率分别为0.69/1000人年和0.21/1000人年,IDR=3.27(95%CI 2.63-4.06)。
  • 风险独立于肥胖、饮酒、糖尿病、病毒性肝炎等经典肝病危险因素,5年landmark分析排除早期事件后仍成立。
  • 基于载脂蛋白B水平或基因定义HBL的敏感性分析结果相似。

关键数值与推荐

  • HBL定义为LDL-C低于同年龄同性别第5百分位。
  • 对照组为LDL-C第40-60百分位。
  • CONSTANCES平均LDL-C:HBL组71 mg/dl,对照组128 mg/dl;UKBB平均LDL-C:HBL组86 mg/dl,对照组142 mg/dl。
  • 肝脏并发症定义为肝硬化并发症和/或原发性肝癌。

临床怎么用

  • 对原发性低β脂蛋白血症患者应考虑定期肝脏监测,具体监测方案有待进一步研究。
  • 临床评估肝病风险时,低LDL-C不应仅视为心血管保护因素,还需关注肝脏并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Beyond cardiovascular disease protection, the health consequences of very low concentrations of low-density lipoprotein-cholesterol (LDL-C) remain a matter of debate. In primary hypobetalipoproteinemia (HBL), liver steatosis and cirrhosis have occasionally been reported. Here, we aimed to investigate the association between HBL and the risk of hepatic complications (cirrhosis complications and/or primary liver cancer) in the general population. METHODS: A cohort study was conducted in the French population-based cohort CONSTANCES. Participants with primary HBL (LDL-C <5th percentile for age and sex, [HBL]) were compared with those with normal LDL-C concentrations (40th-60th percentile, [Control]). Participants on lipid-lowering therapies were excluded. For hepatic complications, follow-up events were compared by calculating the incidence density ratio (IDR). The same analyses were replicated in the UK Biobank (UKBB) cohort. RESULTS: In the CONSTANCES and UKBB cohorts, 34,653 and 94,666 patients were analyzed, with median ages of 45 and 56 years, mean LDL-C concentrations (HBL vs. control) of 71 vs. 128 mg/dl and 86 vs. 142 mg/dl, and mean follow-up durations of 5.0 and 11.5 years, respectively. The HBL group presented a higher incidence of hepatic complications than the control group: 0.32/ vs. 0.07/1,000 person-years (IDR = 4.50, 95% CI 1.91-10.6) in CONSTANCES, and 0.69/ vs. 0.21/1,000 person-years (IDR = 3.27, 95% CI 2.63-4.06) in the UKBB. This risk proved to be independent of classic risk factors for liver disease (obesity, alcohol consumption, diabetes, viral hepatitis), including in a 5-year landmark analysis excluding early events. Sensitivity analyses based on apoliprotein-B levels (instead of LDL-C levels) or genetically defined HBL showed similar results. CONCLUSIONS: HBL is associated with a markedly increased risk of hepatic complications. HBL must be considered as a substantial independent risk factor for liver diseases which justifies specific prevention and screening. IMPACT AND IMPLICATIONS: Hypobetalipoproteinemia (HBL) is a lipid disorder characterized by permanent, inherited low levels (below the 5th percentile) of low-density lipoprotein-cholesterol. While HBL is associated with a lower risk of cardiovascular events, some studies suggest that it may be associated with a potential risk of hepatic steatosis and hepatic complications. Here, we studied the association between HBL and hepatic complications (defined as cirrhosis complications and/or primary liver cancer) in two populations of several hundred thousand people, both in France (CONSTANCES cohort) and the United Kingdom (UKBB). The results show that HBL is associated with a significant and independent excess risk of hepatic complications, including primary liver cancer. Thus, in people with HBL, the value of regular liver monitoring must be studied.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wargny M, Goronflot T, Rimbert A, et al. Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population. J Hepatol. 2024. PMID: 38331324. doi:10.1016/j.jhep.2024.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。